R-7128NS5B inhibitor CAS# 940908-79-2 |
2D Structure
- Anguizole
Catalog No.:BCC1365
CAS No.:442666-98-0
- Asunaprevir (BMS-650032)
Catalog No.:BCC1374
CAS No.:630420-16-5
- Balapiravir
Catalog No.:BCC1396
CAS No.:690270-29-2
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 940908-79-2 | SDF | Download SDF |
PubChem ID | 16122663 | Appearance | Powder |
Formula | C18H26FN3O6 | M.Wt | 399.41 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | RG 7128; Mericitabine; PSI 6130 diisobutyrate | ||
Solubility | DMSO : 100 mg/mL (250.37 mM; Need ultrasonic) | ||
Chemical Name | [(2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-4-methyl-3-(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate | ||
SMILES | CC(C)C(=O)OCC1C(C(C(O1)N2C=CC(=NC2=O)N)(C)F)OC(=O)C(C)C | ||
Standard InChIKey | MLESJYFEMSJZLZ-MAAOGQSESA-N | ||
Standard InChI | InChI=1S/C18H26FN3O6/c1-9(2)14(23)26-8-11-13(28-15(24)10(3)4)18(5,19)16(27-11)22-7-6-12(20)21-17(22)25/h6-7,9-11,13,16H,8H2,1-5H3,(H2,20,21,25)/t11-,13-,16-,18-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | R-7128(Mericitabine) is a selective nucleoside analog inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. | |||||
Targets | HCV |
R-7128 Dilution Calculator
R-7128 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.5037 mL | 12.5185 mL | 25.0369 mL | 50.0739 mL | 62.5923 mL |
5 mM | 0.5007 mL | 2.5037 mL | 5.0074 mL | 10.0148 mL | 12.5185 mL |
10 mM | 0.2504 mL | 1.2518 mL | 2.5037 mL | 5.0074 mL | 6.2592 mL |
50 mM | 0.0501 mL | 0.2504 mL | 0.5007 mL | 1.0015 mL | 1.2518 mL |
100 mM | 0.025 mL | 0.1252 mL | 0.2504 mL | 0.5007 mL | 0.6259 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
R-7128 is a selective nucleoside analog inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase.
Hepatitis C virus (HCV) is an enveloped (+)-single stranded RNA virus, and the viral RNA is replicated in host cell via HCV's RNA-dependent RNA polymerase, which is the cause of hepatitis C and some cancer lymphomas.
R-7128 is a nucleotide triphosphate analog which is the substrate for HCV polymerase NS5B. Incorporation of R-7128 into nascent HCV RNA strongly decreased the efficiency of RNA elongation by RNA polymerase NS5B, leading to the termination of the nascent RNA product. It has been shown that R-7128 is able to inhibit the RNA synthesis of HCV in vitro [1].
32 patient infected with HCV genotype-1 was treated with R-7128 for 14 days with 750-mg or 1500-mg administered once (QD) or twice daily (BID), and the HCV RNA level was frequently measured. Initial decline of HCV RNA was generally slower than treatment with interferon-alpha or protease inhibitors but 12 patients showed a novel pattern of HCV RNA kinetics that the effectiveness in inhibiting viral production gradually increased over time to reach its final value. The final value was high with BID dose (mean 750-mg and 1500-mg: 98.0% and 99.8%, P=0.018) and significantly higher than in patients treated QD (mean QD vs BID: 90% vs 99%, P<10^-7) [2].
References:
[1] Ma H et al. , Characterization of the metabolic activation of Hepatitis C virus nucleoside inhibitor β-D-2′-Deoxy-2′-fluoro-2′-C-methylcytidine (PSI-6130) and identification of a novel active 5′-Triphosphate species. J Biol Chem. 2007, 282(41): 29812-20.
[2] Guedj J et al. , Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology. 2012, 55(4): 1030-1037.
- Poliumoside
Catalog No.:BCN1204
CAS No.:94079-81-9
- Suplatast Tosylate
Catalog No.:BCC4961
CAS No.:94055-76-2
- NVP-BHG712
Catalog No.:BCC3963
CAS No.:940310-85-0
- N,N'-Bis(salicylidene)ethylenediamine
Catalog No.:BCC9064
CAS No.:94-93-9
- Piperine
Catalog No.:BCN1018
CAS No.:94-62-2
- 2-Amino-6-ethoxybenzothiazole
Catalog No.:BCC8541
CAS No.:94-45-1
- Benzyl nicotinate
Catalog No.:BCC8874
CAS No.:94-44-0
- Butylparaben
Catalog No.:BCN8418
CAS No.:94-26-8
- Tetracaine
Catalog No.:BCC9175
CAS No.:94-24-6
- Chlorpropamide
Catalog No.:BCC4647
CAS No.:94-20-2
- Benzyl 4-hydroxybenzoate
Catalog No.:BCC8869
CAS No.:94-18-8
- Sodium 4-amiropparaty Hyalrate
Catalog No.:BCC3855
CAS No.:94-16-6
- SB743921
Catalog No.:BCC4559
CAS No.:940929-33-9
- KD 5170
Catalog No.:BCC2420
CAS No.:940943-37-3
- 1'-Acetonaphthone
Catalog No.:BCC8446
CAS No.:941-98-0
- 1,3,5-Cadinatriene-3,8-diol
Catalog No.:BCN4486
CAS No.:941227-27-6
- Selaginellin
Catalog No.:BCN8215
CAS No.:941269-84-7
- Ruxolitinib (INCB018424)
Catalog No.:BCC1276
CAS No.:941678-49-5
- INCB032304
Catalog No.:BCC6455
CAS No.:941685-27-4
- S-Ruxolitinib (INCB018424)
Catalog No.:BCC2201
CAS No.:941685-37-6
- 8beta-(4'-Hydroxytigloyloxy)costunolide
Catalog No.:BCN7885
CAS No.:94190-32-6
- Methyl 3-indolecarboxylate
Catalog No.:BCN4487
CAS No.:942-24-5
- VTP-27999
Catalog No.:BCC2048
CAS No.:942142-51-0
- SCH772984
Catalog No.:BCC1935
CAS No.:942183-80-4
[Inhibitors of hepatitis C virus--current standards and status of investigations].[Pubmed:21473060]
Przegl Epidemiol. 2010;64(4):473-8.
The current standard of chronic hepatitis C therapy is the combined use of pegylated IFN-alpha 2a (PegIFN-alpha) and rybavirin (RBV). The new form of interferon, IFN-alpha 2b, was also introduced with no better results. Overall, the effectiveness of therapy with the use of the above scheme is not satisfactory. Thus the search for new therapeutic agents for hepatitis C is ongoing. These studies have the goal to find new preparations inhibiting the replication cycle of HCV. The new analogue of RBV, eg. tarybavirin was introduced, with lesser side effects, but the same effectiveness. The activity of new agents relies upon the inhibition of the most important enzymes of the HCV replication cycle: RNA polymerase, protease and helicase. Polymerase NS5 inhibitors are divided into nucleoside (R-7128) and nonnucleoside (ANA-598, GS 9190, VCH-759, VX-222). The intensive studies on the R-7128 analogue are ongoing. The effects of action of particular compounds in the I and II studies were summarized. The promised prodrug is nonnucleoside polymerase inhibitor, ANA-598 which when administrated to patients, gave 75% SVR. The combined administration of the newly described agents is the basis of specifically targeted antiviral therapies for HCV (STAT-C). These therapies allow to achieve better effectiveness of treatment, its shortening, the diminishment and limitation of side effects.